Methods for modulating brain damage
Methods are disclosed for modulating brain damage mediated by non-NMDA ionotropic glutamate receptor antagonists, as topiramate, in conditions such as periventricular leukomalacia, cerebral palsy, mental retardation and neonatal stroke.
1. A method for treating periventricular leukomalacia (PVL), mental retardation, and/or neonatal stroke in a human subject comprising administering to the human subject topiramate and a pharmaceutically acceptable carrier such that PVL, mental retardation, and/or neonatal stroke is treated.
2. The method of claim 1 , wherein said human subject is a neonate.
3. A method for treating PVL, mental retardation, and/or stroke in a human fetus comprising administering to a pregnant mother topiramate and a pharmaceutically acceptable carrier such that PVL, mental retardation, and/or stroke is treated in the fetus.
4. A method for treating grey and/or white matter injury in the brain of a perinatal subject comprising administering to the perinatal subject topiramate and a pharmaceutically acceptable carrier such that grey and/or white matter injury in the brain is treated.
5. A method for treating grey and/or white matter injury in the brain of a fetal subject comprising administering to a pregnant mother topiramate and a pharmaceutically acceptable carrier such that grey and/or white matter injury in the brain of the fetal subject is treated.